Aadi bioscience presents two abstracts on fyarro (nab-sirolimus) at the annual meeting of the connective tissue oncology society (ctos)

Los angeles, nov. 13, 2021 (globe newswire) -- aadi bioscience, inc. (“aadi”) (nasdaq: aadi), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mtor pathway genes, today announced two oral presentations that were made related to its lead candidate, fyarro™ (abi-009 or nab-sirolimus) at the connective tissue oncology society (ctos) 2021 annual meeting, held virtually from november 10-13, 2021. ctos is a multi-disciplinary group of specialized physicians, medical professionals and scientists from around the world who connect and share their knowledge, experiences and research for the advancement of treatment of sarcomas. both studies, sponsored by aadi, provided data in patients with advanced malignant pecoma, which is the clinical indication currently under review by the food and drug administration (fda) with a november 26, 2021 target prescription drug user fee act (pdufa) date.
AADI Ratings Summary
AADI Quant Ranking